Slide 1: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Notice Regarding Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 2: Q4 and FY 2012 Investor Call
Q4 and FY 2012 Investor Call July 12, 2012
Slide 3: Q4 and FY 2012 Investor Call
Q4 and FY 2012 Investor Call July 12, 2012 AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved.
Slide 4: Agenda
AGENDA Integration Update Quality Call to Action Update Outlook for FY 2013 and Beyond Q4 Accomplishments Q4 and FY 2012 Review
Slide 5: Q4 Accomplishments
Q4 ACCOMPLISHMENTS • Closed acquisition of Navilyst; Integration on schedule • Grew VenaCure EVLT™ 17% • Grew NanoKnife® 54% • Grew International business 22% (1) • Published two new NanoKnife® studies • Commenced Microsulis international distribution agreement • Launched Embarc™ microcatheter and C
Slide 6: Integration Update
Announcement Jan 31, 2012 Closing May 22 • Significant pre-closing planning effort paying off • $5-7 million in FY13 cost savings accomplished • Most organizational changes completed • Management team now in place - best talent from both organizations o New CTO o New Head of Quality • Creation of th
Slide 7: Quality Call to Action Update
• Up to date on all QCTA objectives and commitments to the FDA • Significantly improved quality capabilities through acquisition of Navilyst QUALITY CALL TO ACTION UPDATE COST AND GROSS MARGIN IMPACT OF QCTA & PRODUCT RECALLS ¯ 2.6% Impact on GM% ¯ 2.5% ¯ 4.3% Impact on GM% Impact on GM% ¯ 1.4% ¯ 0.
Slide 8: Q4 2012 Results, As Reported and Adjusted
$in millions, except per share eeoaaie As Reported Note Ww Seles oo17 +10% ex Navilyst and LC Beads % growth 43% Vascular Sales $28.3 4 % growth ona +10% ex Navilyst Onc/Surg Sales $11.4 #118 ex Beads % growth -38% Us. sales $47.6 +9% ex Navilyst and LC Beads % growth -2% Inti’Sales $10.1 +22% const
Slide 9: FY 2012 Results, As Reported and Adjusted
Sins xen sore As Reported Note WW sales $221.8 +4% ex Navilyst and LC Beads % growth 43% Vascular Sales $159.1 P % growth a +3% ex Navilyst Onc/Surg Sales $62.7 49% ex Beads % growth 5% US Sales $188.2 41% ex Navilyst and LC Beads % growth Flat Inti sales $33.6 +22% constant currency ex Navilyst % g
Slide 10: FY 2012 Pro Forma Operating Results
FY 2012 PRO FORMA OPERATING RESULTS Pro Forma Operating Results : • Include Navilyst as if combined for all of FY • Exclude LC Beads and related S&M costs • Exclude acquisition, restructuring, financing, QCTA and product recall costs
Slide 11: A New Day for AngioDynamics
Vascular Access VA Peripheral Vascular PV Oncology/ Surgery O/S Long-term Financial Objectives The angiodynamics Mission A NEW DAY FOR ANGIODYNAMICS… • BioFlo™ as a platform technology • Advanced techniques and procedures • New technologies • Automated Fluid Management • Comprehensive venous strateg
Slide 12: FY13 Outlook for Our Global Businesses
FY13 OUTLOOK FOR OUR GLOBAL BUSINESSES
Slide 13: Peripheral Vascular Business
Reinvigorate NAMIC Expand Ablation Grow Core PV PERIPHERAL VASCULAR BUSINESS • Channel Synergy - Fluid Mgmt in IR/Vascular - Venous Ablation in Cardiology - Core Products in Cardiology • NeverTouch Direct™ Launch + = FY 2013 Strategic Objectives Key Growth Drivers Financial Expectations (1) Pro Form
Slide 14: Vascular Access Business
Penetrate & Convert BIOFLO BIOFLO BIOFLO VA VASCULAR ACCESS BUSINESS • BioFlo™ PICCs (pending 510(k) clearance) • BioFlo™ Ports (pending 510(k) clearance) • BioFlo™ Dialysis (pending 510(k) clearance) • Strategic Acquisitions + = FY 2013 Strategic Objectives Key Growth Drivers Financial Expectations
Slide 15: BioFlo Technology
NO HEPARIN NO ANTIBIOTICS NOT A COATING NOT ELUTING VA BIOFLO™ TECHNOLOGY Coatings Impregnated (in the pores) Current Next Generation PICC Technologies Minimizes complications associated w/ heparin Reduces risks associated w/ bacterial resistance Present throughout entire catheter Present for life o
Slide 16: BioFlo Technology: Head-to-Head Data
Metric PowerPICC Solo 2 BioFlo w/ PASV PICCs Placed 60 133 Occlusion Rate 9.63/1,000 catheter days 4.96/1,000 catheter days T-PA Usage Rate 12.84 doses/1,000 catheter days 7.93 doses/1,000 catheter days DVT Rate 0.80/1,000 catheter days 0.50/1,000 catheter days VA BIOFLO™ TECHNOLOGY (cont’d) Head-to
Slide 17: Oncology / Surgery Business
Drive NanoKnife Adoption Deliver the Most Comprehensive Ablation Solution O/S Continue to Fill Channel ONCOLOGY / SURGERY BUSINESS • NanoKnife® Data • International Microwave • Embarc™ Microcatheter and Charter™ Guidewire launches • Strategic Transactions + = FY 2013 Strategic Objectives Key Growth
Slide 18: NanoKnife Proposed Pancreatic IDE Trial
O/S NANOKNIFE® PROPOSED PANCREATIC IDE TRIAL HEAD-TO-HEAD EVALUATION Gemcitabine vs. NanoKnife® + Gemcitabine in patients with uncresectable pancreatic cancer • Randomized controlled trial • Comparison vs. standard-of-care (gemcitabine) • 190 patients w/ confirmed stage III disease • Primary endpoin
Slide 19: A New U.S. Go-To-Market Strategy
VP Sales Area Sales Director VA Sales Rep PV Sales Rep O/S Sales Rep GPOs IHN/IDN Hospitals CEOs/CFOs/ Purchasing Managers Doctors IRs/ICs/ Surgeons/Nurses VA Specialist PV Specialist O/S Specialist Regional Managers Oncology/ Surgery Peripheral Vascular Vascular Access A NEW U.S. GO-TO-MARKET STRAT
Slide 20: FY13 Financial Guidance
FY13 FINANCIAL GUIDANCE Key FY13 Objectives • Drive sales synergies with new call points and more focused sales efforts • Meet/exceed cost saving goals by aggressively implementing the integration program • Strong product launches of BioFlo™ in the U.S., NeverTouch Direct®, Microsulis and microcathe
Slide 21: Financial Aspirations for FY14 and Beyond
FINANCIAL ASPIRATIONS FOR FY14 AND BEYOND Key Long-term Objectives • NanoKnife as standard of care • Continue to introduce innovative products and technologies, including automated fluid management systems, next-generation ablation solutions and venous intervention products • Sustained international
Slide 22: Q4 and FY 2012 Investor Call
Q4 and FY 2012 Investor Call July 12, 2012 AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved.
Slide 23: Business Development Summary
Business Development Summary: • 18 active discussions 1 - $750M- $1.5B of cumulative 5-yr sales • Relatively balanced portfolio - Stage of development: Ø 8 (45%) Commercial; 10 (55%) R&D 1 - Business Focus: Ø 8 (45%) Vascular; 10 (55%) Oncology 1 • Most Oncology targets are fairly small - $350M - $5
Slide 24: Reconciliation of Net Income to non-GAAP Net Income
- Only Microsulis >$50M of cum. 5-yr sales Reconciliation of Net Income to non-GAAP Net Income
Slide 25: Reconciliation of Diluted Earnings (Loss) Per Share to Non-GAAP
Reconciliation of Diluted Earnings (Loss) Per Share to Non-GAAP Diluted Earnings Per Share